ASH tackles COVID-19 with hematology-related FAQ, promotes new registriesApril 14, 2020Multiple Myeloma
First report of MM patient successfully treated for COVID-19 with tocilizumabApril 6, 2020Multiple MyelomaOncology
Maintaining cancer care in the face of COVID-19April 1, 2020Genitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersLung CancerMultiple MyelomaMelanoma
New CAR T-cell therapy eliminates MM and tumor propagating cells without fratricide in lab studyFebruary 26, 2020Multiple MyelomaHematologyOncology
Myeloma patients over age 70 can benefit from auto-HC transplantDecember 7, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematologyOncology
Bispecific CAR T-cells yield high response rate in relapsed/refractory myelomaDecember 7, 2019Multiple MyelomaOncologyLymphoma & Plasma Cell Disorders
High complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersOncologyHematology
Early lenalidomide may delay progression of smoldering myelomaNovember 19, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersOncologyHematology
Levofloxacin prophylaxis improves survival in newly diagnosed myelomaNovember 1, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematology
Progressive myeloma after induction? Go straight to transplantSeptember 6, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
SC daratumumab deemed feasible for every multiple myeloma patientJuly 11, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematology
Daratumumab regimen shows benefit in transplant-ineligible myelomaMay 29, 2019Multiple MyelomaLymphoma & Plasma Cell DisordersHematology
